News & Events

Reflecting on a year of achievements and learning at SeQure Dx

As the calendar flips to 2024, we at SeQure Dx find ourselves at an exhilarating crossroads. With a year of groundbreaking achievements behind us and the horizon filled with promising opportunities, we’re eager to share our journey and the future we’re passionately working towards.

Reflecting on 2023: A Year of Milestones

The past year has been nothing short of extraordinary for our team. We’ve not only participated in but also shone at several prestigious conferences, including the American Society of Hematology and the Cell & Gene Meeting on the Mesa. Our presentation at the American Society of Gene and Cell Therapy, highlighting the critical role of population heterogeneity evaluation in off-target analyses, was particularly well-received.

One of our proudest moments in 2023 was forging a strategic partnership with KromaTiD. This collaboration has been instrumental in offering comprehensive, IND-enabling gene-editing services that have significantly advanced cell and gene therapy research. Our journey through the year was marked by numerous such partnerships, contributing to our growth and the gene-editing field at large.

The strides we’ve made in commercialization underscore our commitment to enhancing the precision and safety of gene therapies. Our focus on guide RNA selection and off-target analysis has not only solidified our position in the industry but also supported our partners in navigating the complexities of market introduction.

The Gene Editing Therapy Milestone

The groundbreaking approval of gene-editing therapies by the FDA marks a new chapter in medical history. These therapies, offering potential cures for diseases like sickle cell disease, represent a quantum leap in healthcare. We extend our congratulations to our friends at Vertex Pharmaceuticals and CRISPR Therapeutics for their pioneering work on Casgevy, the first CRISPR-based therapy to be FDA approved in the US. 

At SeQure Dx, we’re proud to be at the forefront of gene editing safety and the approval of Casgevy has given the entire gene editing community a great way to kick off 2024.

Looking Forward to 2024: What’s Next?

In another pivotal move for gene therapy, the FDA has just unveiled comprehensive guidance for human gene therapy products involving genome editing. This landmark announcement provides much-needed clarity for those who are developing these products. You can read the full guidance here, and in our view this will:

  1. Accelerate the development of new gene therapies
  2. Improve the safety of gene therapy products
  3. Increase public confidence in gene therapy by providing transparency and underscores the need for correct off-target analysis.

Our roadmap for the year is filled with innovative plans and initiatives. We’re particularly excited about participating in the ASGCT conference in May, where we’ll present our latest research and product advancements. 

Furthermore, our recent partnership with Synthego, aimed at providing comprehensive off-target analysis services, is just the beginning of our collaboration efforts to advance gene editing.

Join Us on This Exciting Journey

As we embark on this journey through 2024, we invite you to join us in these exciting times at SeQure Dx. Stay connected with us on LinkedIn for regular updates on our progress, insights into the gene editing world, and our contributions towards shaping the future of healthcare.

Thank you for being part of our story. Here’s to a year filled with breakthroughs and advancements that will shape the future of medicine.